Four‐fold increased mortality rate in patients with Wilson's disease: A population‐based cohort study of 151 patients

BACKGROUND AND AIMS: Few studies have investigated mortality rates in patients with Wilson's disease and compared these to the general population. Here, we examined several clinical outcomes (including cardiovascular, psychiatric, neurologic conditions) in a population‐based study of patients with Wilson's disease. METHOD: We used nationwide registers to identify all patients with a first diagnosis of Wilson's disease between 2002 and 2020 in Sweden. Each patient was matched by age, sex, and municipality with up to 10 reference individuals from the general population. Validated registers were used to investigate outcomes up to 19 years after baseline in patients and reference individuals. RESULTS: We identified 151 patients with Wilson's disease matched with 1441 reference individuals. Median age at baseline was 26 years (IQR 17–42) and 50% were males. During a median follow‐up of 6.6 years (IQR 2.9–12.9), 10 (6.6%) patients with Wilson's disease died compared with 31 (2.2%) reference individuals. This translated to a hazard ratio (HR) of 3.8 (95%CI = 1.8–8.1). Mortality was higher among Wilson's disease patients with baseline neuropsychiatric diagnoses (HR 7.9, 95%CI = 2.9–21.8). Cumulative mortality over 10 years was 9.3% (95%CI = 5.0–16.8) in Wilson's disease, compared to 2.4% (95%CI = 1.6–3.6) in reference individuals. We observed significantly elevated risks in the Wilson's disease group for incident cardiovascular disease, and incident psychiatric and neurological conditions when considering liver transplantation or death from other causes as competing events. CONCLUSION: In this large population‐based cohort study, patients with Wilson's disease had an almost four‐fold increased mortality rate compared with matched individuals from the general population.